J, M., A, C., MC, C., M, G., F, G., S, M., . . . M, S. (2021). Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Citación estilo ChicagoJ, Mora, et al. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. 2021.
Cita MLAJ, Mora, et al. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. 2021.
Precaución: Estas citas no son 100% exactas.